Thromboembolic risk in the initiation, switch and interruption/re-initiation of oral anticoagulants: Do newcomers improve outcomes? Insights from a meta-analysis of RCTs

International Journal of Cardiology

Volumn 177, Issue 1, 2014, Pages 117-119

  Caldeira, Daniel ^a   Costa, João ^a,b   Ferreira, Joaquim J ^a   Pinto, Fausto J ^c  

^a UNIVERSITY OF LISBON   (Portugal)

^b Portuguese Collaborating Center of the Iberoamerican Cochrane Network   (Portugal)

^c INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Apixaban; Dabigatran; Initiation; Interruption; Meta analysis; Rivaroxaban

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K;

DRUG RECHALLENGE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LETTER; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETREATMENT; RISK ASSESSMENT; RISK REDUCTION; THROMBOEMBOLISM; TREATMENT WITHDRAWAL; ATRIAL FIBRILLATION; COMPLICATION; META ANALYSIS (TOPIC); ORAL DRUG ADMINISTRATION; STROKE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; HUMANS; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; TREATMENT OUTCOME;

EID: 84909977526     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.09.099     Document Type: Article

References (10)

1. L. Azoulay, S. Dell'Aniello, T.A. Simon, C. Renoux, and S. Suissa Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes Eur Heart J 35 2014 1881 1887
2. M.R. Patel, A.S. Hellkamp, Y. Lokhnygina, J.P. Piccini, Z. Zhang, and S. Mohanty Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) J Am Coll Cardiol 61 2013 651 658
3. D. Siegal, J. Yudin, S. Kaatz, J.D. Douketis, W. Lim, and A.C. Spyropoulos Periprocedural heparin bridging in patients receiving VKA: systematic review and meta-analysis of bleeding and thromboembolic rates Circulation 126 2012 1630 1639
4. C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, and M. Hanna Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
5. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, and A. Parekh Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
6. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, and W. Hacke Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
7. M. Hori, M. Matsumoto, N. Tanahashi, S. Momomura, S. Uchiyama, and S. Goto Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation - the J-ROCKET AF study - Circ J 76 2012 2104 2111
8. J.S. Healey, J. Eikelboom, J. Douketis, L. Wallentin, J. Oldgren, and S. Yang Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial Circulation 126 2012 343 348
9. M.W. Sherwood, J.D. Douketis, M.R. Patel, J.P. Piccini, A.S. Hellkamp, and Y. Lokhnygina Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF) Circulation 129 2014 1850 1859
10. H.C. Diener, C.B. Granger, and M.R. Patel Is there a period of liability with initiation of warfarin in patients with atrial fibrillation? Eur Heart J 35 2014 1834 1835